MRTX1133 obtained clearance as an investigational new drug (IND) by the FDA in October 2021 for a phase I/II clinical trial (NCT05737706), targeting patients with advanced solid tumors (PDAC, NSCLC, colorectal cancer, and others) harboring the KRAS G12D mutation [81]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.